[
    {
        "file_name": "ANIXABIOSCIENCESINC_06_09_2020-EX-10.1-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "1.4 \"Invention\" means any invention, know-how, data, discovery or proprietary information, whether or not patentable, that is made or generated solely by the Representatives of Anixa or OntoChem or jointly by the Representatives of Anixa and OntoChem in performing the Research Plan, including all intellectual property rights in the foregoing.",
                "changed_text": "1.4 \"Invention\" means any invention, know-how, data, discovery or proprietary information, whether or not patentable, that is made or generated solely by the Representatives of Anixa in performing the Research Plan, including all intellectual property rights in the foregoing.",
                "explanation": "By removing the clause related to 'OntoChem or jointly by the Representatives of Anixa and OntoChem', the definition of 'Invention' now favors Anixa's intellectual property ownership, contradicting potential joint ownership claims later in the agreement.",
                "location": "Section 1.4"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "2.4 Selection of Lead Scaffolds. Within one year following completion of all activities under the Research Plan (the \"Selection Deadline\"), Anixa, in good faith consultation with OntoChem, will have the right to select up to two hundred (200) Hit Compounds (each, a \"Selected Hit Compound\"), by providing OntoChem with written notice of such Selected Hit Compound(s) (the \"Selection Notice\"), and each Selected Hit Compound, along with all Variants of such Selected Hit Compound referenced in the Selection Notice, is hereby designated as a \"Lead Scaffold\" under this Agreement.",
                "changed_text": "2.4 Selection of Lead Scaffolds. Within one year following completion of all activities under the Research Plan (the \"Selection Deadline\"), Anixa will have the right to select up to two hundred (200) Hit Compounds (each, a \"Selected Hit Compound\"), by providing OntoChem with written notice of such Selected Hit Compound(s) (the \"Selection Notice\"), and each Selected Hit Compound, along with all Variants of such Selected Hit Compound referenced in the Selection Notice, is hereby designated as a \"Lead Scaffold\" under this Agreement.",
                "explanation": "Removing 'in good faith consultation with OntoChem' contradicts the collaborative spirit implied in the 'WHEREAS' clause and other sections, potentially leading to disputes about the fairness of Lead Scaffold selection.",
                "location": "Section 2.4"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "6.4 License Grant. OntoChem hereby grants to Anixa a non-exclusive, fully paid-up, royalty-free, perpetual, irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses through multiple tiers) under any patents which OntoChem or any of its Affiliates own or control during the term of this Agreement, to make, have made, use, sell, offer for sale and import the Lead Scaffold(s) and products that incorporate compounds from the Lead Scaffold(s).",
                "changed_text": "6.4 License Grant. OntoChem hereby grants to Anixa a non-exclusive license under any patents which OntoChem or any of its Affiliates own or control during the term of this Agreement, to make, have made, use, sell, offer for sale and import the Lead Scaffold(s) and products that incorporate compounds from the Lead Scaffold(s). The specifics of the license, including payment, duration, and geographical limitations, will be subject to further negotiation and written agreement between the parties.",
                "explanation": "By removing 'fully paid-up, royalty-free, perpetual, irrevocable, transferable, worldwide license (with the right to grant and authorize sublicenses through multiple tiers)' and adding 'The specifics of the license, including payment, duration, and geographical limitations, will be subject to further negotiation and written agreement between the parties.', the clause creates uncertainty around the license terms, contradicting the original clause.  This uncertainty could lead to disputes over usage rights and royalty obligations.",
                "location": "Section 6.4"
            }
        ]
    }
]